Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

9.603 +0.013 (+0.13%)
Streaming Delayed Price Updated: 10:03 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Fujifilm To Buy Cell Therapy Plant From Atara For $100M ↗
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, will acquire a cell therapy plant from Atara Biotherapeutics Inc (NASDAQ: ATRA)  
Via Benzinga
News headline image
The Daily Biotech Pulse: Galapagos Appoints J&J Exec As CEO, Aridis Gets Funding For Antiviral Treatment, Moderna Starts Omicron-Specific Booster Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
From Be The Match BioTherapies
Via Business Wire
News headline image
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
News headline image
Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients ↗
Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
News headline image
20 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement... 
Via Benzinga
News headline image
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
News headline image
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed ↗
Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a... 
Via Benzinga
News headline image
Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript ↗
ATRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
News headline image
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.